- Home
- TIL vs CRGX Comparison
TIL vs CRGX Comparison
Compare TIL & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- CRGX
- Stock Information
- Founded
- TIL 2018
- CRGX 2021
- Country
- TIL United States
- CRGX United States
- Employees
- TIL N/A
- CRGX N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- TIL Health Care
- CRGX
- Exchange
- TIL Nasdaq
- CRGX Nasdaq
- Market Cap
- TIL 230.1M
- CRGX 213.5M
- IPO Year
- TIL 2021
- CRGX 2023
- Fundamental
- Price
- TIL $31.69
- CRGX $4.52
- Analyst Decision
- TIL Buy
- CRGX Hold
- Analyst Count
- TIL 5
- CRGX 7
- Target Price
- TIL $119.00
- CRGX $5.33
- AVG Volume (30 Days)
- TIL 263.6K
- CRGX 3.0M
- Earning Date
- TIL 08-12-2025
- CRGX 08-11-2025
- Dividend Yield
- TIL N/A
- CRGX N/A
- EPS Growth
- TIL N/A
- CRGX N/A
- EPS
- TIL N/A
- CRGX N/A
- Revenue
- TIL N/A
- CRGX N/A
- Revenue This Year
- TIL N/A
- CRGX $57.81
- Revenue Next Year
- TIL N/A
- CRGX N/A
- P/E Ratio
- TIL N/A
- CRGX N/A
- Revenue Growth
- TIL N/A
- CRGX N/A
- 52 Week Low
- TIL $9.85
- CRGX $3.00
- 52 Week High
- TIL $92.00
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- TIL 60.55
- CRGX 54.72
- Support Level
- TIL $25.58
- CRGX $4.40
- Resistance Level
- TIL $32.76
- CRGX $4.63
- Average True Range (ATR)
- TIL 2.55
- CRGX 0.07
- MACD
- TIL 0.75
- CRGX -0.01
- Stochastic Oscillator
- TIL 89.55
- CRGX 34.29
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.